Latest Board Composition News

HITIQ Limited reported a $2.9 million loss for the half-year ending December 2025, while making significant strides in international market expansion and strategic partnerships. The company’s capital raising efforts aim to support its transition from technology validation to commercial execution.

Tetratherix Limited reported a $4.6 million statutory loss for the first half of FY26, driven by increased R&D and manufacturing investments, while making significant progress in clinical trials and securing key global partnerships.

Invex Therapeutics reports a net loss of $715,582 for H1 2026 while advancing its Exenatide program targeting neurological diseases, alongside notable board reshuffles.

Manhattan Gold Limited has reshaped its board and management team following the full acquisition of the Hook Lake Project, signalling a strategic pivot towards advancing this key asset.

Aland Equity Group Limited has completed significant capital raisings and board restructuring while navigating a challenging quarter for its flagship Growth Fund. The company is positioning itself for expansion into property funds management.

QMines Limited has made significant strides in its Queensland projects with high-grade drilling results at Mount Mackenzie and Develin Creek, backed by a $9 million capital raise to support exploration and development.

Genesis Minerals has restructured its executive team, appointing Raleigh Finlayson as Executive Chair and promoting Matthew Nixon to CEO, positioning the company for a significant growth phase.

Li-S Energy has made significant strides in Q4 2025, securing a major government grant, forging key defence partnerships, and commissioning Australia’s first lithium foil production line.

BSA Limited has announced immediate changes to its board, including the appointment of Daniel Raihani as Chair and the addition of Piers Lewis as a Non-Executive Director, signaling a fresh chapter in governance.

Cycliq Group Ltd reported a 21% decline in customer receipts for Q2 FY2026, offset by a solid net operating cash inflow and a strong Black Friday campaign that generated $1.3 million in gross revenue.

Invex Therapeutics reports promising new data from its collaboration with Tessara Therapeutics on Exenatide’s potential in Alzheimer’s disease, alongside significant board changes and a solid cash position at quarter’s end.

Southern Cross Media Group has completed its acquisition of Seven West Media, issuing new shares and announcing key leadership and board changes that reshape Australia's media landscape.